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New insights into the pretargeting approach
to image and treat tumours
Malay Patra,a Kristof Zarschler,*b Hans-Ju¨rgen Pietzsch,b Holger Stephanb and
Gilles Gasser*a
Tumour pretargeting is a promising strategy for cancer diagnosis and therapy allowing for the rational
use of long circulating, highly specific monoclonal antibodies (mAbs) for both non-invasive cancer
radioimmunodetection (RID) and radioimmunotherapy (RIT). In contrast to conventional RID/RIT where the
radionuclides and oncotropic vector molecules are delivered as presynthesised radioimmunoconjugates, the
pretargeting approach is a multistep procedure that temporarily separates targeting of certain tumour-
associated antigens from delivery of diagnostic or therapeutic radionuclides. In principle, unlabelled, highly
tumour antigen specific mAb conjugates are, in a first step, administered into a patient. After injection,
suﬃcient time is allowed for blood circulation, accumulation at the tumour site and subsequent elimination
of excess mAb conjugates from the body. The small fast-clearing radiolabelled eﬀector molecules with a
complementary functionality directed to the prelocalised mAb conjugates are then administered in a second
step. Due to its fast pharmacokinetics, the small eﬀector molecules reach the malignant tissue quickly and
bind the local mAb conjugates. Thereby, corresponding radioimmunoconjugates are formed in vivo and,
consequently, radiation doses are deposited mainly locally. This procedure results in a much higher tumour/
non-tumour (T/NT) ratio and is favourable for cancer diagnosis and therapy as it substantially minimises the
radiation damage to non-tumour cells of healthy tissues. The pretargeting approach utilises specific non-
covalent interactions (e.g. strept(avidin)/biotin) or covalent bond formations (e.g. inverse electron demand
Diels–Alder reaction) between the tumour bound antibody and radiolabelled small molecules. This tutorial
review descriptively presents this complex strategy, addresses the historical as well as recent preclinical and
clinical advances and discusses the advantages and disadvantages of different available variations.
Key learning points
(1) Monoclonal antibodies (mAbs) are excellent tools to target tumour associated antigens, but the straightforward approach of utilising directly radiolabelled
mAbs for radioimmunodetection (RID) and radioimmunotherapy (RIT) of tumours is aﬀected by their unfavourable biodistribution.
(2) The pretargeting approach is a multistep procedure that temporarily separates targeting of tumour associated antigens by mAb conjugates from delivery of
diagnostic or therapeutic radionuclides.
(3) The pretargeting approach can boost the tumour/non-tumour ratio and thus limits the radiation dose for healthy tissues.
(4) The pretargeting approach utilises specific non-covalent interactions (e.g. strept(avidin)/biotin or hybridisation of oligonucleotides) as well as covalent bond
formations (e.g. inverse electron demand Diels–Alder reaction) between the tumour bound antibody conjugates and radiolabelled small molecules.
1. Introduction
Early diagnoses, quantitative imaging, eﬃcient treatment and
precise monitoring of anticancer therapy require extremely
sensitive detection methodologies such as the nuclear medicinal
imaging techniques single-photon emission computing tomo-
graphy (SPECT) and positron emission tomography (PET). In
addition to these, the use of a highly tumour-specific vehicle
labelled with a radionuclide as reporter for radioimmuno-
detection (RID) or warhead for radioimmunotherapy (RIT) is
essential to achieve high sensitivity and specificity.1 These
aﬃne oncotropic vector molecules with appropriate pharmaco-
kinetic and pharmacodynamic properties become increas-
ingly important as an alternative to, or in combination with,
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conventional treatments such as surgery, chemotherapy and
external radiotherapy.2
Monoclonal antibodies (mAbs) bind cognate antigens with
excellent specificity and thus represent indispensable mole-
cules for therapeutic and diagnostic applications. Since their
introduction more than 60 years ago, radiolabelled mAbs
have been extensively evaluated in preclinical and clinical
settings for delivering radioactivity to tumour sites to visua-
lise, characterise, and treat tumour malignancies including
primary and metastatic cancers.3 The potential of this so
called conventional RID/RIT is evidenced by the approval of
two radioimmunotherapeutic mAbs, namely ibritumomab
tiuxetan (Zevalins) and tositumomab (Bexxars), by the U.S.
Food and Drug Administration (FDA) for treatment of non-
Hodgkin’s lymphoma (NHL). While both Zevalins and Bexxars
are composed of mAbs directed against the CD20 antigen
which is overexpressed in B-cell lymphomas, they bear
diﬀerent radionuclides. In the clinic, the 111In-labelled form
of Zevalins is used for diagnostic imaging or RID, whereas
90Y-Zevalins is used for RIT. Bexxars was approved in
combination with the radioisotope 131I for treatment of
NHL.4 The principles, issues and challenges associated with
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RIT, radionuclides used in RIT as well as the latest progress
in this field have been the subject of numerous comprehen-
sive reviews,2,3,5,6 and the interested reader is directed to
these to obtain further information on that particular topic.
Despite their success in the clinic, the concept of utilising
radioimmunotherapeutic mAbs is aﬄicted with several
important shortcomings.4,7 mAbs are known for their high
stability and prolonged circulation in the blood, slow biodis-
tribution kinetics and slow clearance from the body. Due to
the poor tissue penetration abilities of radiolabelled mAbs, a
delayed clearance from the blood is required to achieve
higher accumulation of radioactivity in tumours. But, at
the same time, this prolong circulation appears as one of
the most important drawbacks of conventional RID/RIT.3
It causes undesired radiation burden in healthy tissues,
especially in the bone marrow, which is extremely sensitive
to radiation. This limits the opportunity of enhancing the
eﬃcacy of therapy by increasing the dose of radiolabelled
mAbs. Additionally, slow clearance of radiolabelled mAbs
from blood and healthy tissues often results in a lower
tumour/non-tumour (T/NT) ratio and – for RID – it requires
extensive waiting periods before image acquisition. Rapid
clearance of radiolabelled mAbs from the blood and non-
targeted tissue is therefore beneficial in order to obtain a
higher T/NT ratio. As a consequence, the pharmacokinetic
properties of mAbs appear as the main dilemma in conven-
tional RID/RIT approach.7 Fortunately, however, several of
these shortcomings can be eliminated by implementing the
pretargeting strategy allowing for the rational use of long
circulating, high-affinity mAbs for both non-invasive cancer
RID and RIT.8
2. Detailed explanation of the
pretargeting strategy
In contrast to conventional RID/RIT where the radionuclides
and oncotropic vector molecules are delivered as presynthesised
radioimmunoconjugates (Fig. 1A), the pretargeting strategy is
a multistep procedure that decouples targeting of tumour asso-
ciated antigens from radionuclide delivery (Fig. 1B). All pretarget-
ing systems share in principle two basic components: (i) a target
specific component, often a non-radioactive mAb conjugate
capable of binding a certain tumour antigen as well as (ii) a
small radiolabelled eﬀector component. As schematically repre-
sented in Fig. 1, unlabelled, highly tumour specific mAb con-
jugates are in a first step administrated into a patient. After
injection, suﬃcient time, also referred to as pretargeting interval,
is allowed for blood circulation, accumulation at the tumour site
and subsequent elimination of excess mAb conjugates from the
body. Importantly, as the mAb conjugates themselves are not
radiolabelled, the pretargeting interval can be extended to several
days for optimal T/NT ratios without the risk of radiation
exposure to healthy tissues. At the time when the concentration
of mAb conjugates at the tumour site is at its peak and much
higher than in healthy tissues, small fast-clearing radiolabelled
eﬀector molecules with a complementary functionality directed
to the prelocalised mAb conjugates are administered in a second
step. Due to its fast pharmacokinetics, the small eﬀector mole-
cules reach the malignant tissue quickly and bind the local mAb
conjugates, thereby forming radioimmunoconjugates in vivo. The
excess eﬀector molecules are rapidly excreted from the blood or
healthy tissues, resulting in a higher T/NT ratio which is favour-
able for diagnostics and therapy. A hallmark of all pretargeting
procedures therefore represents the minimised radiation expo-
sure of non-targeted tissue as well as limited haematological
toxicity.3 Following its initial demonstration by Reardan and his
team in 1985,9 the pretargeting strategy has become an area of
extensive research and extremely promising results have been
reported over the last decades.10,11
Although the pretargeting approach improves the T/NT ratio
significantly over conventional RID/RIT, it should be, however,
remembered that the pretargeting strategy comes with several
complexities which are absent in conventional RID/RIT.
Conventional targeting has two variables, namely the doses of
radiolabelled mAbs and time of detection. In general, provided
the mAb binding sites are unsaturated, the accumulation of
radioactivity in tumour is only slightly influenced by the doses
of the radiolabelled mAb but greatly varies with the detection
time. The optimisation of conventional RID/RIT in clinical
setting is therefore relatively easy. On the contrary, even the
simplest two-step pretargeting strategy involves four variables,
namely the doses of pretargeting mAb conjugates, the pretar-
geting interval, the doses of radiolabelled eﬀector molecules
and the time of detection. The accumulation of radioactivity,
which is now not in the mAb but in the secondary eﬀector
agent, is highly influenced by the changes in any of these four
variables. Additionally, there are three system-associated vari-
ables in the pretargeting approach (e.g. the mAb conjugates,
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the radiolabelled secondary eﬀector agent and the type of tumour)
compared to only two in conventional RID/RIT (e.g. the radio-
labelled vector molecule and the type of tumour). Complexity
further increases with increasing the number of steps, making
the optimisation very diﬃcult in clinical settings. The optimisa-
tion of a pretargeting system is carried out experimentally in
practice by varying diﬀerent variables using trial and error
methods. The optimised parameters are also not broadly applic-
able to any system, but strictly specific to a particular pretargeting
system. Therefore, optimisation of variables is required for each
pretargeting system undergoing clinical trial and such optimisa-
tion is not very practical. Liu and Hnatowich proposed a semi-
empirical model for pretargeting RID/RIT, which is capable of
estimating how the optimal tumour accumulation and T/NT ratio
is influenced by the diﬀerent combination of variables. The
model is based on several quantitative equations relating the
dependence of diﬀerent pretargeting variables on the outcome.
For the details of this model, from the design to the applicability,
readers are directed to the excellent review published by the
pioneer of this model.12 This semiempirical model has thus far
been applied only to a MORFs/cMORFs (MORF = phospho-
diamidate morpholino oligomers) pretargeting system. More
and more experimental data on other pretargeting systems is
required to predict the true applicability of this semiempirical
model on the optimisation of pretargeting variables without an
exhaustive trial and error method.
All the pretargeting systems introduced to date can be
classified into two broad categories depending on the interactions
between the pretargeted mAb conjugates and the radiolabelled
small eﬀector molecules: (i) non-covalent high aﬃnity interaction
and (ii) covalent bond formation using bioorthogonal chemistry.
These two categories are presented in detail below.
3. Non-covalent high aﬃnity
interactions
3.1 Recognition systems based on bispecific antibodies
The initial pretargeting concept described more than 30 years
ago pursued the strategy to apply bispecific (bs) monoclonal
antibodies (mAbs) capable of binding both tumour antigens as
well as radiolabelled chelates (Fig. 2).11
The first generation of bs mAbs-based pretargeting systems
originally involved bs mAbs consisting of a single anti-tumour
Fab fragment that was chemically conjugated to a single anti-
chelate Fab fragment resulting in both monovalent binding to
the tumour antigen as well as to the radiometal–chelate
complex (Fig. 2A).7 In the initial preclinical and clinical studies
Fig. 1 Schematic presentation of conventional radioimmunodetection (RID) and radioimmunotherapy (RIT) with directly radiolabelled mAbs (A) and
pretargeting procedure using mAb conjugates and small radiolabelled eﬀector molecules (B). Conventional RID/RIT uses radionuclide-carrying tumour
specific mAbs with long blood retention times resulting in detrimental radiation exposure of healthy tissues (A). In contrast, the pretargeting approach
starts with the intravenous administration of unlabelled, highly tumour specific mAb conjugates into the patient. After accumulation of the mAb
conjugates at the tumour site and clearance from non-targeted tissues, small fast-clearing radiolabelled eﬀector molecules are injected that bind to the
prelocalised mAb conjugates at the tumour site (B).
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using this pretargeting system, Fab fragments against the carcino-
embryonic antigen (CEA) were combined with Fab fragments
binding to DTPA. Since antibodies bound to CEA do not readily
internalise and thus remain accessible at the surface of tumour
cells, this particular tumour antigen is especially suitable for
pretargeting. Taking full advantage of this behaviour, an extended
time period for clearance of the bs mAbs of up to eight days can
be allowed before injection of the fast-clearing radiometal–chelate
complexes. Compared to directly radiolabelled but long circulating
anti-CEA IgG antibodies, improved tumour-to-blood and tumour-
to-liver ratios were obtained using the two-step pretargeting
method due to the fast clearance of the radiolabelled chelates.13
Although this pretargeting system was successfully tested in
patients with primary colorectal cancer,14 the radiolabelled
chelates were rapidly released from the tumour site due to their
weak monovalent interactions with the pretargeted bs mAbs.
Higher tumour uptake and retention were achieved by gradually
improving the diﬀerent components of the monovalent binding
system. The second generation of bs mAbs based pretargeting
systems deployed short peptides linking two radiometal–chelate
complexes instead of monomeric radiolabelled chelates (Fig. 2B).7
These bivalent probes interact with the anti-chelate Fab fragment
of the prelocalised bs mAbs with enhanced avidity resulting
in enhanced tumoural uptake and retention.11 The group of
Kraeber-Bode´re´ intensively investigated this second generation
pretargeting procedure regarding the treatment of CEA-
producing medullary thyroid carcinoma (MTC) in several pre-
clinical as well as clinical studies10 and critically compared the
toxicity and efficacy of pretargeted RIT with those of conven-
tional RIT.15
The first as well as second generation of bs mAbs-based
pretargeting systems utilised anti-chelate antibodies with an
exceptional specificity for a certain radiometal–chelate complex,
e.g. 111In-loaded DTPA. The major drawback of these approaches
was that the binding affinity dropped substantially, when other
radiometals were complexed by the same chelator as observed for
90Y– or 177Lu–DTPA. This limited flexibility necessitated, in the
worst case, the generation of new antibodies with high affinity for
the desired radiometal–chelate pairs, e.g. directed against 90Y– or
177Lu–DOTA, in order to expand these pretargeting systems to a
wide variety of radionuclides.13
To circumvent this limitation, the anti-chelate Fab fragment
of the bs mAbs was replaced by a Fab fragment binding to an
inert compound composed of histamine-succinyl-glycine (HSG)
with nanomolar aﬃnity. An additional small peptide core of
three to four D-amino acids serves on one hand as a metabo-
lically stable scaﬀold to link two HSG moieties resulting in
a bivalent HSG-peptide. On the other, the peptide can be
modified in diﬀerent ways to attach diverse ligands capable
of binding the radionuclide of choice. This included the
(3-thiosemicarbazonyl)glyoxylcysteinyl (Tscg-Cys) moiety for
complexing of 99mTc and 188Re as well as DOTA for chelating
111In, 68Ga, 177Lu and 90Y for diagnostic or therapeutic applications,
respectively. Furthermore, incorporation of a tyrosine residue into
the peptide sequence also allowed for radioiodination.11
For the third generation of bs mAbs-based pretargeting
systems, bs mAbs with two binding sites for the tumour antigen
and one for the HSG-peptide were prepared by a modular
approach termed Dock-and-Lock procedure (Fig. 2C).7 This
innovative and sophisticated system stably joins one Fab frag-
ment of an anti-HSG antibody and two Fab fragments of an
anti-tumour antibody (tri-Fab bs mAbs) in a manner to allow
for bivalent binding to the tumour antigen and monovalent
binding of the radiolabelled HSG-peptide. Due to its bivalency,
a single HSG-peptide can crosslink two nearby tri-Fab bs mAbs
at the surface of tumour cells leading to the formation of a
stable complex. For detailed information on the Dock-and-Lock
method the interested reader is directed to an excellent review
of Rossi et al.16
Several clinical trials for identifying optimal treatment para-
meters and assessing safety as well as tolerance of the third
generation of bs mAbs-based pretargeting system in humans
were started in patients with metastatic colorectal and lung
cancer as well as medullary thyroid carcinoma, respectively.
The corresponding results of these optimisation studies using
anti-CEA tri-Fab bs mAbs in combination with 111In and 68Ga
Fig. 2 Development of bs mAbs-based pretargeting. The first generation
of bs mAbs-based pretargeting systems involved bs mAbs consisting of a
single anti-tumour Fab fragment chemically conjugated to a single anti-
chelate Fab fragment resulting in monovalent binding to the tumour
antigen as well as to the chelate (A). The second generation of bs mAbs-
based pretargeting systems utilised bivalent peptide-linked chelates possibly
bridging two adjacent bs mAbs (B). Bs mAbs with two binding sites for the
tumour antigen and one for the HSG-peptide (tri-Fab) were prepared in the
third generation bs mAbs based pretargeting system. The radiolabelled
eﬀector molecule was modified to a bivalent HSG-peptide (C).
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(for imaging) or 177Lu (for therapy) labelled bivalent HSG-
peptides were reported recently.17–20 Points of particular note
are in this context the fast and selective tumour visualisation
within hours after injection of the radiolabelled di-HSG-peptides
subsequently to pretargeting with the anti-CEA tri-Fab bs mAbs
as well as fast clearance from non-targeted tissues and organs
resulting in high tumour-to-normal tissue ratios. Moreover,
injected radiation doses of 177Lu ranging from 2.5–7.4 GBq
resulted only in limited haematological toxicity, and no signs or
symptoms of renal toxicity were observed.
Of possible importance for repeated administration of bs
mAbs is the appearance of immune responses in a number
of patients such as infusion reactions and the formation of
human antibodies against the tri-Fab bs mAbs although huma-
nised recombinant antibody constructs were injected. The
presence of such antibodies during a therapy cycle may aﬀect
the pharmacokinetics of the bs mAbs and influence the quality
of tumour targeting, whereas the former adverse event is
manageable by appropriate anti-allergic premedication with
antihistamines and corticosteroids injected.17,19
In summary, the bs mAbs-based pretargeting systems have
been intensively investigated in preclinical as well as several
clinical studies for RID and RIT of cancer and documented in
detail. These systems appear on one hand suitable for RID by
immuno-PET, when the eﬀector molecules are labelled with
short half-life positron-emitters such as 68Ga or 64Cu. On the
other hand, ongoing clinical trials will analyse their performance
for RIT as promising preclinical studies have demonstrated the
very fast delivery of high radiation doses to tumour tissues with
limited exposure of non-targeted tissues.
3.2 Avidin/streptavidin–biotin recognition system
The avidin/streptavidin–biotin system relies on the very high
affinity of (strept)avidin for biotin and was initially introduced
by Donald J. Hnatowich and members of his group.21 Up to four
biotin molecules (also known as vitamin B7, vitamin H or
coenzyme R) can bind to theB66 kDa glycoprotein avidin with
an dissociation constant Kd of 10
15 M. This is one of the
strongest known non-covalent interactions, whereas their asso-
ciation is rapid, and, once formed, this complex is stable to
extremes of pH and in the presence of denaturing agents or
organic solvents. Of note, the non-glycosylated bacterial analo-
gue of avidin, streptavidin (B56 kDa), is interchangeable with
avidin in in vitro studies. However, for in vivo applications, the
difference in glycosylation between the two proteins makes
them suitable for different purposes as naturally glycosylated
avidin, in contrast to non-glycosylated streptavidin, is rapidly
sequestered by the liver.22 Worthy of note, streptavidin was
reported to show less non-specific binding to tissues compared
to avidin.21 The avidin/streptavidin–biotin system requires
either the conjugation of (strept)avidin to mAbs or the generation
of biotinylated mAbs. Both configurations have been reported
frequently and differ in their application regime.22
The two-step method starts with the intravenous injection of
anti-tumour streptavidin mAb conjugates (Fig. 3A). Their high
molecular weight (B210 kDa) results in a slow blood clearance
and necessitates the removal of excess streptavidin mAb con-
jugates from the blood pool by administration of a clearing
agent prior to the injection of the radiolabelled biotin molecules.
Once the concentration of the streptavidin mAb conjugates peaks
at the tumour site, the clearing agent (e.g. biotinylated galactose-
conjugated human serum albumin) is given to transport circulating
streptavidinmAb conjugates to the liver, where they aremetabolised
and withdrawn from circulation.22
In contrast, the three-step method of the avidin/streptavidin–
biotin system uses biotinylated antitumour mAbs and glycosy-
lated avidin as clearing agent, which is given once the biotinylated
mAbs have achieved maximum tumour uptake (Fig. 3B). After the
circulating complex composed of avidin and biotinylated mAbs is
transported to the liver, unlabelled streptavidin is administered.
Upon reaching the malignant tissue, these multivalent proteins
strongly bind to the prelocalised biotinylated mAbs. Finally, radio-
labelled biotin molecules are injected and interact with tumour-
bound complexes of streptavidin and biotinylated mAbs.22
Fig. 3 Schematic representation illustrating the two-step (A) and three-
step (B) method of the avidin/streptavidin–biotin pretargeting system. The
two-step method includes the injection of anti-tumour streptavidin mAb
conjugates to pretarget the malignant tissue. Once the streptavidin mAb
conjugates have achieved maximum tumour uptake, a clearing agent is
applied to remove the streptavidin mAb conjugates from the blood
circulation before radiolabelled biotin is given (A). The three-step method
starts with the administration of biotinylated anti-tumour mAbs localising
to the malignant tissue. After the injection of the clearing agent, unlabelled
streptavidin is given to bind the pre-localised biotinylated mAbs at the
tumour site. Finally, radiolabelled biotin is injected to interact with tumour-
bound complexes of streptavidin and biotinylated mAbs (B).
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In their seminal paper, Hnatowich and co-workers investi-
gated the in vivo application of mAbs linked to (strept)avidin
or biotin followed by the administration of 111In-labelled
(strept)avidin or biotin. They could demonstrate that the intra-
venous administration at first of avidin mAb conjugates followed
by radiolabelled biotin was more beneficial than the reverse
procedure (i.e. injection of biotin mAb conjugates followed by
radiolabelled streptavidin). Indeed, the authors observed an
unfavourable slow blood clearance of 111In-labelled streptavidin
and its accumulation in normal tissue. Promisingly, using
protein-A conjugated beads to simulate tumours, Hnatowich
and his team showed that T/NT ratios were increased by more
than two orders of magnitude over the conventional use of a
single intravenous administration with radiolabelled mAb.21
Following this pioneering work, several research groups have
employed this in vivo recognition system in view of imaging
and treatment of tumours using diﬀerent radionuclides (e.g. 111In,
153Sm, 90Y, 177Lu and 211At).23,24
Due to space constrains, it is impossible to report individually
each study on this recognition system. Thus, we have decided,
in the next paragraph, to only highlight the results of clinical
studies that have utilised the avidin/streptavidin–biotin system
in pretargeting. For detailed information on the application
of this recognition system in cancer diagnosis and therapy,
the interested reader is directed to two excellent reviews by
Lesch et al. and Stoldt et al., respectively, as well as references
therein.23,24
To the best of our knowledge, Hnatowich and his team were
the first researchers to report a clinical study. Specifically,
streptavidin was conjugated to mouse mAbs directed against
a component of human milk fat globule membranes and
reacting strongly with a range of neoplasms. These streptavidin
mAb conjugates were intravenously administered to ten patients
with documented squamous cell carcinoma of the lung. Two to
three days later, 111In-labelled biotin was injected and patients
were imaged 2 h after the administration for detection of lung
cancer lesions. Importantly, no toxicity for the patients at the
doses tested was evidenced in this study. Background radio-
activity levels were found to be low in liver and kidneys as well as
in other normal tissues and blood. In fact, the radioactivity levels
in liver and kidney were improved by at least one order of
magnitude and by a factor of five, respectively, compared to
conventional approach using directly radiolabelled mAbs.23
Shortly afterwards, the Milanese group of Giovanni Paganelli
and co-workers described two diagnostic clinical trials on the
two-step as well as three-step method of the avidin/streptavidin–
biotin system. The former study was conducted on ovarian
cancer patients and the latter focussed on carcinoembryonic
antigen-positive patients. Both trials utilised biotinylated mAbs
and provided a deep insight into pharmacokinetics, biodistribu-
tion and tumour localisation. In particular, their elaborated
three-step pretargeting protocol avoids the issues of slow blood
clearance of radiolabelled (strept)avidin and its accumulation in
normal tissues. According to the authors, the advantages of this
three-step method over other pretargeting approaches or direct
radiolabelling of mAbs are manifold. Firstly, the small size of the
radiolabelled biotin molecules ensures their rapid renal elimina-
tion and allows for diagnostic imaging already shortly after
injection. As the retention time in the body is thereby reduced,
the radiation exposure of liver and bone marrow is minimised.
Secondly, circulating biotinylated antitumour mAbs interact with
the clearing agent avidin and both molecules are metabolised
by the mononuclear phagocyte system of the liver as non-
radioactive complex leading to background reduction. Thirdly,
the mild reaction conditions applied for biotinylation of the
mAbs preserve their immunoreactivity. As the mAbs are not
directly labelled, also their radiolysis is prevented. Fourthly,
signal amplification can potentially be achieved through the
multivalency of streptavidin. In theory, multiple streptavidin
molecules can bind to prelocalised biotinylated mAbs and
multiple radiolabelled biotin molecules can finally interact
with tumour-bound complexes of streptavidin and biotinylated
mAbs. And fifthly, the three-step pretargeting protocol resulted
in substantial improvement of T/NT ratios within a few hours
after injection of the radiolabelled effector molecules expanding
the range of suitable radionuclides.24
Finally, the authors mentioned that their technique presents
a few drawbacks, namely repeated injections at defined time
intervals and the immunogenicity of avidin. The latter, very
important point will be discussed later in this section of the
review.
The same research group conducted in the following years
several diagnostic and therapeutic studies on patients with
diﬀerent cancer entities including head and neck cancer as
well as glioblastoma.13,25 Of note, the delivery of therapeutic
radionuclides, in particular 90Y, by the three-step method of the
avidin/streptavidin–biotin system in patients with high-grade
glioma resulted in tumour mass reduction and survival benefit.
In comparison to conventional RIT using directly labelled
mAbs, this pretargeting approach indeed allows for the admini-
stration of high 90Y activities enabling delivery of a high dose to
the tumour and sparing red marrow and other normal organs.13
At this stage, although promising clinical trials were indeed
undertaken, as already discussed above, it is important to high-
light that the avidin/streptavidin–biotin recognition system still
presents several drawbacks. As mentioned by Goldenberg et al.,
who debated with Giovanni Paganelli and Marco Chinol on the
viability of this recognition system in pretargeting, immuno-
genicity is problematic.26,27 The immune system of patients
recognises the foreign biotin and produces antibodies against
the biotin after the first injection. Upon a second application, the
biotin can initiate a severe immune reaction. Also, the production
of the antibody–protein conjugate is relatively complicated and
its diffusion/adsorption is relatively slow due to its relatively
large size.
3.3 Recognition systems based on in vivo hybridisation
of synthetic complementary oligonucleotides
DNA as well as RNA oligonucleotides of a certain sequence
rapidly bind their complementary strands with a very high
specificity and aﬃnity. However, natural occurring nucleic
acids are highly susceptible to nuclease-mediated hydrolysis
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and possess therefore an insuﬃcient in vivo stability. For that
reason, several synthetic non-immunogenic DNA analogues with
excellent chemical and metabolic stability have been developed
as recognition systems for tumour pretargeting including peptide
nucleic acids, phosphorodiamidate morpholino oligomer and
mirror-imaged oligonucleotides (Fig. 4).
3.3.1 Morpholino nucleic acids as recognition units. Phos-
phordiamidate morpholino oligomers (morpholinos or MORFs)
are a distinct class of non-ionic oligonucleotide analogues. In
these synthetic molecules, a morpholine-phosphorodiamidate
backbone replaces the ribofuranose-phosphodiester linkage
present in natural DNA and RNA (Fig. 4B). This backbone
makes morpholinos water-soluble and resistant against enzymatic
degradation by nucleases. Despite their altered backbone, mor-
pholinos bind to their complementary nucleic acid sequences
by Watson–Crick base-pairing. Advantageously, while the
ribofuranose-phosphate backbone in DNA and RNA is chiral,
there is no such complexity in hybridisation of morpholino
oligomers.28 Pioneering work in the application of morpholinos
to the field of radiopharmaceutical was performed by Hnatowich
and co-workers, who demonstrated the first proof-of concept use
of tumour pretargeting in mice using 18mer MORF and its 99mTc-
labelled 18mer complementary MORF (cMORF).28 The underlying
principle is illustrated in Fig. 5.
The anti-CEA antibody MN14, conjugated with amine-modified
MORF, hybridises with 99mTc-labelled MAG3–cMORF-conjugate
to achieve pretargeting in tumour-bearing mice. MAG3 (mercapto-
acetyl triglycine) is a tripeptide chelator especially designed for
stable binding of 99mTc in its oxidation state +5. Biodistribution
studies demonstrated good radioactivity uptake in tumour.
However, the 99mTc-labelled cMORF effector molecule also
accumulated in the kidneys and intestines. This accumulation
may be problematic for tumour imaging (or tumour therapy)
within the abdomen. To overcome this obstacle, changing the
radionuclide, and consequently, the chelator can be considered.
It is well-documented that radiolabelling with different radio-
nuclides via different chelators may alter the pharmacokinetics
of even large molecules such as peptides or antibodies. Conse-
quently, Hnatowich et al. compared pharmacokinetics of
99mTc–MAG3–cMORF and
111In–DTPA–cMORF in normal mice
in a further study.29 Therein tumour-bearing mice were
pretargeted with the appropriate MORF-antibody. 48 h later
99mTc–MAG3–cMORF and
111In–DTPA–cMORF, respectively,
were then injected and the mice were reimaged. The authors
clearly demonstrated that the biodistribution of the cMORF
effector was influenced by the appropriate chelate unit both in
normal and pretargeted tumour-bearing mice. As illustrated in
Fig. 6, accumulation of 111In–DTPA–cMORF in the intestines
was minimal compared with the intestinal accumulation of
99mTc–MAG3–cMORF.
After demonstrating the rapid tumour accumulation and
normal tissue clearance of the 99mTc-labelled MAG3–cMORF/
MN14–MORF pretargeting system, Hnatowich et al. reported
the first preclinical mouse-model of MORF pretargeting for RIT
using the b-emitting radionuclide 188Re. 188Re was selected as
the therapeutic radionuclide because of its attractive properties
for radiotherapy. It is a generator-based nuclide with a half-life
of 17 h and an average b-energy of about 2 MeV. A g-radiation
component of 0.155 MeV allows for SPECT imaging. Further-
more, diagnostic 99mTc and therapeutic 188Re form a so-called
‘‘matched pair’’ of radionuclides showing similar coordination
properties. This similarity often results in radiolabelled agents
with similar, if not identical, properties.
The proof-of-principle study was performed using 188Re–MAG3–
cMORF/MN14–MORF with 14.8 GBq 188Re per mouse and three
control groups (untreated mouse, injection of MN14–MORF alone,
Fig. 4 Schematic drawing comparing deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) with peptide nucleic acids (PNA, A), phosphorodiamidate
morpholino oligomer (B) and mirror-imaged oligonucleotides (C).
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injection of 188Re–MAG3–cMORF alone) and resulted in fast accu-
mulation of 188Re in tumour accompanied by rapid clearance from
normal tissues. The tumour accumulation was about four times
higher than in the kidney and blood, which were the healthy
tissues with highest radioactivity uptake. Tumour growth in
the study group ceased one day after radioactivity injection,
whereas tumours continued to grow at the same rate among the
three control groups. The therapeutic success was confirmed by
measuring the tumour size. On the fifth day after treatment, the
average net tumour weight was significantly lower for the study
group compared with the three control groups.30
A second preclinical study treating LS174T-tumour bearing
mice using 188Re–MAG3–cMORF and an MORF-modified
antiTAG-72 mAb CC49 was published by Hnatowich et al. four
years later. As shown by SPECT/CT, the radioactivity uptake was
highly tumour specific for the two time points given: 3.5 and
10 h after injection (Fig. 7). Except for the intense urine radio-
activity at 3.5 h, the radioactivity is essentially restricted to
tumour at both time points. Tumour growth was inhibited for
the treated mice and at the highest 188Re dose, a complete but
temporary tumour remission was evident in three out of five
animals. Histological examination of tissues from these animals
showed no evidence of cytotoxicity to normal tissues but obvious
radiation damage to the tumour.31
From a radiopharmaceutical point of view, the trivalent
metals In3+ and Y3+ constitute another ‘‘matched pair’’ of
radionuclides. 90Y is considered as an alternative to 188Re with
comparable b-energy but of longer half-life (2.2 MeV, 64 h)
that can potentially improve radiotherapy eﬀectiveness. 90Y will
Fig. 5 Principle of using oligomeric nucleic acids and synthetic DNA analogues for tumour pretargeting. In this pretargeting approach, an unlabelled,
highly specific mAb–oligonucleotide conjugate has sufficient time to target a tumour before administration of a small fast-clearing radiolabelled
complementary oligonucleotide that hybridises with the pre-localised mAb–oligonucleotide conjugate at the tumour site (A). Changing the radionuclide
including the chelator may alter the pharmacokinetics of the effector molecule (B).
Fig. 6 Anterior projections of the SPECT/CT fused acquisitions obtained
at two time points in normal mice receiving either 99mTc–cMORF (left
panel) or 111In–cMORF (right panel). Bladder 99mTc and 111In radioactivity
were digitally removed in all projections, as was the 111In contamination on
the animal’s coat in the 68 min 111In projection. Adapted with permission
from ref. 29, copyright Springer.
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provide higher tumour-to-organ absorbed radiation dose because
a larger portion of the circulating 90Y will be cleared without
depositing its energy in the normal tissues.
Based on the pretargeting study described above using
188Re–MAG3–cMORF, Hnatowich and co-workers performed a
therapeutic pretargeting experiment using 90Y-labelled cMORF
sequences.32 Due to the different coordination chemistry of
yttrium compared to rhenium, the chelator MAG3 was substi-
tuted by the macrocyclic ligand DOTA forming a 90Y–DOTA–
cMORF/MORF–CC49 pretargeting system. The biodistribution
was measured in both normal and LS174T-tumour bearing
mice, and the pharmacokinetics of the 90Y–DOTA–cMORF
in both the normal the pretargeted mice was comparable to
that observed previously with 188Re–MAG3–cMORFs. While the
90Y–DOTA–cMORF cleared rapidly from normal tissues, tumour
clearance was very slow and tumour radioactivity accumulation
was constant for at least seven days allowing for the T/B ratio to
increase linearly from 6 to 25 over this period. Therefore, by
extrapolation, normal tissue toxicities following administration
of therapeutic doses of 90Y may be comparable to that observed
for 188Re in which the T/B ratio increased from 5 to 20 over a
7 day period. Furthermore, due to the longer physical half-life,
the tumour-to-non-tumour absorbed radiation dose ratios were
improved in most organs and especially in blood.
Of note, the authors clearly showed that both the pharmaco-
kinetics and pretargeting behaviour of the cMORF eﬀector is
generally not influenced by the nature of the chelator and the
radionuclide using 188Re–MAG3–cMORF and
90Y–DOTA–cMORF.
In summary, the preclinical studies performed by the group
of Hnatowich have clearly demonstrated the suitability and
eﬀectiveness of the morpholino-based pretargeting system, with
high T/B ratios but no clinical trials have been initiated yet.
3.3.2 Peptide nucleic acid as recognition units. In 1991,
Nielsen et al. reported on the synthesis and characterisation of
thymine-based oligonucleotides where the deoxyribose phos-
phate backbone of DNA was replaced by a polyamide backbone.
They named it polyamide nucleic acids. Meanwhile, this class
of artificial oligonucleotides is well-known as peptide nucleic
acids (PNAs).33 PNAs contain repetitive N-(2-aminoethyl)-glycine
units attached to nucleobases via a methylcarbonyl linker to give
a flexible, non-chiral and non-charged pseudo-peptide polyamide
backbone (Fig. 4A). Due to the lack of electrostatic repulsion,
PNAs rapidly hybridise to form more stable duplexes than
PNA/DNA and in particular DNA/DNA.33 These oligonucleotides
have been primarily developed as recognition units for double-
stranded DNA. PNAs are characterised by an excellent chemical
and metabolic stability. They are almost inert towards degrada-
tion in vivo and can be synthetically modified to modulate their
intrinsic physico-chemical properties. For example, the attachment
of appropriate spacer elements and specific building blocks, such
as targeting units and solubility enhancers, to both the C- and
N-terminus of PNAs allows for a broad variation of the pharmaco-
logic properties of PNA bioconjugates.33 Of particular interest is
the linkage ofmetal complexes to PNAs. In thismanner, numerous
new applications have been explored.34 Metal-containing PNAs
play an important role in the development of artificial enzymes,
biosensors, DNA-templated metal catalysis, oxidative cross-linkers
to a DNA target. Moreover, metal–PNA conjugates are effective
modulators of PNA/DNA hybrid stability as well as find use as
radioactive probes. With regard to the latter, 99mTc, 111In- and
64Cu-labelled PNAs have been evaluated for brain, breast, small
lymphotic lymphoma and pancreatic cancer imaging.35
The potential of PNAs as an eﬃcient pretargeting system has
been explored by the group of Donald J. Hnatowich for the first
time in 1997.36 A 15-mer PNA oligomer equipped with MAG3 as
chelator was radiolabelled with 99mTc to show rapid renal
clearance in mice. In vivo hybridisation was confirmed using
polymeric beads transplanted into mouse thighs that contain the
complementary PNA strand. The highest amount of radioactivity was
found after 23 h in the transplanted beads. At this time, radioactivity
could only be detected in beads, kidneys and bladder.36
We recently described active tumour pretargeting with PNA
bioconjugates as complementary system. More specifically, we
modified on one hand epidermal growth factor receptor (EGFR)
Fig. 7 Anterior, left lateral and posterior projections for each SPECT/CT acquisition of one pretargeted mouse imaged at 3.5 h (A) and 10 h (B) after
injection of 188Re–cMORF. Adapted with permission from ref. 31, copyright Taylor & Francis Ltd.
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specific therapeutic mAbs (cetuximab) with PNA oligomers
consisting of 17 bases. On the other, we attached dipicolyl (DPA:
N,N-bis(2-picolyl)amine) chelators to complementary PEGylated
PNA oligomers with optimised pharmacological properties.37 It is
worth highlighting that PEGylation of complementary eﬀector
PNAs led to an increased blood residence time without substan-
tially influencing their hybridisation properties. Furthermore, these
PNA conjugates rapidly cleared from the body via the kidneys and
already 1 h postinjection, radioactivity was mostly detected in the
kidneys and bladder (Fig. 8A). Very importantly, rapid and eﬃcient
hybridisation of the complementary 99mTc-labelled eﬀector PNAs
with pretargeted mAb–PNA conjugates was observed in in vivo
experiments using EGFR-positive tumour xenografts (Fig. 8B
and C). This active tumour pretargeting approach permits a clear
visualisation of the tumour just 1 h postinjection of the radio-
labelled effector, achieving tumour-to-muscle ratios48.37
Altogether, PNAs are promising candidates for further
preclinical studies. In this perspective, it is advantageous that
PNA derivatives can be produced with a PNA synthesiser,
allowing for rapid access to a broad range of PNA constructs
in an appropriate amount.
3.3.3 Use of mirror-imaged oligonucleotides as recognition
units. Mirror-imaged oligonucleotides are synthetic RNA or
DNA oligonucleotides based on the non-natural enantiomeric
forms L-ribofuranose or L-deoxyribofuranose, respectively (Fig. 4C).
Due to their L-configuration these compounds are resistant against
enzymatic degradation by nucleases and therefore stable in a
biological environment. Moreover, L-oligonucleotides do not
hybridise with nucleic acids of natural configuration.38 The
rapid hybridisation of complementary mirror-image oligo-
nucleotides, the lack of natural hybridisation targets as well
as their high metabolic stability makes L-oligonucleotides a
promising complementary system for pretargeting approaches.
Schlesinger et al. described the synthesis and radiopharmaco-
logical characterisation of 68Ga- and 86Y-labelled DOTA–12mer-L-
RNA conjugates as molecular probes for PET.39 Biodistribution
studies of the 86Y-labelled 12mer-L-RNA oligonucleotide in
healthy male Wistar rats showed very fast renal elimination
and low retention of the compound in tissues and organs. The
same group investigated the influence of the 86Y–DOTA chelate
moiety on the biodistribution of the 86Y–DOTA–12mer-L-RNA
conjugate in healthy rats.40
The very fast blood clearance combined with high kidney
accumulation of radiolabelled L-oligonucleotides requires opti-
misation to design an eﬃcient pretargeting system. The objective
was to minimise the kidney uptake and non-specific accumulation,
and to increase the blood availability of radiolabelled L-oligo-
nucleotides. Introduction of high-molecular-weight polyethylene
glycol (PEG) moieties into a pharmacologically active substance
is a well-established tool to influence its pharmacokinetics.
Therefore, Foerster et al. investigated the impact of increasing
(2, 5, 10 and 20 kDa) PEG sizes of 68Ga- and 64Cu-labelled
L-oligonucleotide–PEG conjugates on their distribution and
PET kinetics in Wistar rats.41 It could be demonstrated that
tuning of pharmacokinetics is possible by successive PEGylation
resulting in a series of suitable L-oligonucleotides with reduced
kidney uptake, favourable half-life of circulation and very low
unspecific tissue accumulations. The introduction of NOTA or
DOTA as chelating moieties had no influence on the pharmaco-
kinetics and allows radiolabelling with various metallic radio-
nuclides for theranostic applications.
To conclude, the use of mirror-imaged oligonucleotides as
recognition units in pretargeting systems showed great promise
but is only in its infancy. Further studies are definitely required
concerning dosimetry and proof-of-feasibility in vivo.
4. Covalent bond formation using
bioorthogonal chemistry
All pretargeting systems evaluated in the past are promising
but each of them has specific advantages as well as limitations.
Fig. 8 SPECT/CT maximum intensity projection images of [99mTc](Tc-Dpa)–
(Cys-PEG10kDa)–PNA in murine A431 tumour xenograft (NMRI nu/nu mice;
tumour located at right thigh). (A) 1 h postinjection of [99mTc](Tc-Dpa)–(Cys-
PEG10kDa)–PNAwithout preinjection of (NOTA)3-C225-Cys-c-PNA. (B) 1 h post
injection of radiotracer; (NOTA)3-C225-Cys-c-PNA was administered 24 h
before injection of radiotracer. (C) 20 h postinjection of radiotracer; (NOTA)3-
C225-Cys-c-PNA was administered 24 h before injection of radiotracer.
Adapted with permission from ref. 37, copyright Royal Society of Chemistry.
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For example, the streptavidin and biotin couple oﬀers the high-
est binding aﬃnity and was found to be one of the promising
pretargeting systems thus far in clinical settings. However, as
discussed in more detail above, the system is not free from
limitations, such as the induction of immunogenicity caused
by the administration of streptavidin. Moreover, complexity in
engineering, the high cost of production of streptavidin or of the
biotin-attached mAb, and the perturbation of antibody aﬃnity
while attached to streptavidin are additional drawbacks of this
system.42
In the recent past, bioorthogonal reactions have been tested
as an alternative to non-covalent interactions in the pretargeting
strategy. These chemical procedures are relatively straightforward,
less likely to induce immunogenicity and rely on covalent bond
formation between the tumour bound pretargeted mAbs and
the radiolabelled eﬀectors. In this context, it is important to
note that a chemical reaction needs to meet certain criteria to
become truly bioorthogonal and to be useful for this purpose.
Those criteria are, for example, a high stability of the reaction
components in aqueous/biological media, a fast ligation kinetics
even at very low reagents concentration, an occurrence without
external reagent/catalyst, a selective reaction between the com-
ponents and no cross reaction with biological reactants in
cellular environment, a good yield and no generation of toxic
by-products.43 A few click chemistry reactions, namely, the
Staudinger ligation, the strain promoted alkyne–azide cyclo-
addition (SPAAC) and the inverse electron demand Diels–Alder
reaction (IEDAA), satisfy most of the above criteria and have
been evaluated for their potential in pretargeting in cultured
cells as well as in mice (Fig. 9). The progress made especially
with tumour pretargeting using bioorthogonal chemistry was
summarised in a few excellent reviews published recently.42,44,45
We therefore decided to limit our discussion to brief overviews of
the historical developments and a few specific landmark studies
Fig. 9 Schematic drawing of target specific and small fast-clearing radiolabelled eﬀector components as well as their corresponding reaction products
described in bioorthogonal chemistry based tumour-pretargeting approaches. By Staudinger ligation (A), strain promoted alkyne–azide cycloaddition (B)
and inverse electron demand Diels–Alder reactions (C). Covalent bond between the tumour bound pretargeted mAb conjugates and the radiolabelled
effectors are formed at the tumour site.
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on the pretargeting strategy using bioorthogonal reactions. Addi-
tionally, we cover the very recent developments on bioorthogonal
tumour pretargeting that were not included in the previous review
articles.
4.1 Staudinger ligation
In 1919, Staudinger and Meyer reported for the first time a
reaction between an azide and a triphenylphosphine resulting
in an iminophosphorane intermediate which undergoes hydro-
lysis spontaneously in the presence of water to give a primary
amine and corresponding phosphine oxide. More than 80 years
later, Bertozzi and co-workers were the first to realise the potential
of this reaction for biological applications.43 The classical
Staudinger reaction satisfy many of the above mentioned criteria:
it occurs rapidly in water at room temperature and both reactants
are abiotic and react selectively without cross-reaction with bio-
logical media or cell surface proteins. Therefore, this reaction
holds the promise for being applicable in biological environ-
ments. However, the main limitation of this reaction was the
aqueous instability of the iminophosphorane covalent adduct,
that hydrolyses in the presence of water. Using an engineered
triarylphosphine consisting of an ester group as electrophilic
trap within the phosphine, Bertozzi and colleagues were able to
trap the iminophosphorane intermediate intramolecularly, so
that it results in a stable covalent adduct after the rearrangement.
Incorporation of this specific modification transformed the
Staudinger reaction into the Staudinger ligation which is
sometimes also termed as the Staudinger–Bertozzi ligation
(Fig. 9A).43 Over the years, this click reaction became a very
popular tool and found a widespread use including metabolic
labelling of cell surfaces in vitro and in vivo.43
In 2011, van Dongen and co-workers were the first to make
an attempt to evaluate the possibility of the application of
the Staudinger ligation for tumour pretargeting. The authors
therefore modified anti-CD44v6 mAbs with several triazide
functionalities and developed a series of rapidly clearing radio-
labelled phosphines as eﬀector molecules. In order to evaluate
the ligation eﬃciency in vivo, radiolabelled phosphines were
injected in non-tumour bearing mice 2 h after the administra-
tion of triazide–mAbs. Unfortunately, no evidence of in vivo
Staudinger ligation was detected. These negative results pre-
sumably originate from low reaction rates of the Staudinger
ligation at low reagent concentrations. Moreover, rapid oxida-
tion of phosphine to unreactive phosphine oxide in the blood
was also observed representing another concern of this ligation
strategy.45
4.2 Strain promoted alkyne–azide cycloaddition (SPAAC)
A click reaction between cyclooctyne and azide to form a 1,2,3-
triazole unit was first reported by Krebs and Wittig in 1961
(Fig. 9B). The reaction is analogues to the original copper
mediated Huisgen [3+2] alkyne–azide cycloaddition. However,
it proceeds without the need of Cu, which is toxic to living
tissues, but via the release of the strain of the cyclooctyne
moiety. The reaction is termed as strain promoted alkyne–azide
cycloaddition (SPAAC). Furthermore, the reagents are more
compatible to in vivo conditions and the rate of the reaction is
superior compared to the Staudinger ligation.43 At the moment, to
the best of our knowledge, there are only two reports where SPAAC
was evaluated for tumour pretargeting and the findings were
described in recent reviews.42,45
In 2013, the group of Rossin and Robillard prepared triazide-
conjugated anti-CD20 mAbs (Rituximab) as well as a number of
177Lu-labelled DOTA-conjugated cyclooctyne derivatives to assess
the reactivity profile of the triazide–mAbs and the radiolabelled
effector probes in the circulation in non-tumour-bearing mice.
However, the low in vivo reactivity of the generated cyclooctyne
effectors towards azides and their covalent and non-covalent
interactions with serum proteins impeded a sufficient bond
formation between the azido-conjugated mAbs and the 177Lu-
probes in this study.42,45 Soon after that, a report by Kim and
co-workers demonstrated that SPAAC indeed holds promises
for application in tumour pretargeting. In contrast to the study
of Rossin and Robillard, the authors did not use mAb con-
jugates to pretarget the tumour but mesoporous silica nano-
particles that passively accumulate and retain in tumours
through the enhanced permeability and retention (EPR) effect.
These nanoparticles were PEGylated as well as functionalised
with dibenzocyclooctyne (DBCO) and subsequently intravenously
administered into tumour-bearing mice. After a pretargeting
interval of 24 h, the radiolabelled effectors, 18F-labelled azides,
were injected. Following the postinjection interval, PET-CT imaging
indicated an accumulation of radioactivity at the tumour side in
mice pretargeted with the nanoparticles, whereas much less
radioactivity was deposited in the tumours of mice without
nanoparticle pretreatment.42,45 This later study provides a good
indication that SPAAC could, indeed, be used for tumour
pretargeting provided an appropriate cyclooctyne moiety with
favourable reaction kinetics is chosen and a suitable protocol is
applied.
4.3 Inverse electron demand Diels–Alder reaction (IEDDA)
In 2008, the bioorthogonality of inverse electron demand Diels–
Alder reaction (IEDDA) between trans-cyclooctene (TCO) and
tetrazine (Tz) forming pyridazines (Fig. 9C) was disclosed for
the first time.43 The reaction proceeds with a fast rate without
the need of a catalyst, in water, cell media, or in cell lysate and
was found to have a high functional group tolerance. In fact,
IEDDA was shown to be the most promising among the three
bioorthogonal reactions investigated in tumour pretargeting,
especially in vivo, to date. Despite promising results of IEDDA-
mediated pretargeting in cultured cells, its successful transla-
tion into animal requires the IEDDA to satisfy more demanding
criteria: (i) very fast reaction kinetics at low reagent concentra-
tions, (ii) high stability of TCO and Tz moiety in vivo, (iii) prolong
circulation of TCO tagged mAbs, (iv) faster accessibility to
the tumour tissue and (v) rapid clearance of the circulating
Tz-radiolabelled effector molecule from the body.
The in vivo application of IEDDA for pretargeted radio-
diagnostic imaging was first demonstrated in a landmark study
by Robillard and co-workers in 2010. Therein the authors
described the preparation of TCO-conjugated mAbs (CC49)
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directed against the pan-adenoma TAG-72 antigen as target
specific component. 111In-labelled DOTA-Tz probes represent
the small, fast clearing eﬀector component of this pretargeting
approach. The CC49–TCO conjugates were injected into mice
bearing colon cancer xenografts and a pretargeting interval of
1 day was set to allow for their localisation to the malignant
tissue. Upon injection of the radiolabelled Tz derivative, the two
complementary bioorthogonal reactants rapidly reacted in vivo
and SPECT/CT imaging of live mice 3 h postinjection revealed
a pronounced localisation of radioactivity in the tumour and
in the urinary bladder with limited uptake in blood and non-
targeted tissues, such as the liver.45
Over the last few years, significant modifications have been
introduced to this strategy in order to achieve improved T/NT
ratio. For example, TCO and Tz components have been modified
to enhance the rate of ligation, a chaser (clearing reagents)
has been introduced before administration of the radiolabelled
eﬀectors to clear the circulating antibody–TCO conjugates from
the blood, etc. For details on these advancements up to the year
2014, we direct the readers to consult the excellent review articles
published by Knight and Cornelissen as well as Rossin and
Robillard.42,45
Since the last review article in this field, there have been a
few more studies published on this rapidly growing topic. The
group of Jason S. Lewis at the Memorial Sloan Kettering Cancer
Center in New York developed a pretargeted PET imaging
strategy based on IEDDA. Members of this laboratory have
recently developed two novel 64Cu-labelled Tz ligands, 64Cu-
Tz-PEG7-NOTA and
64Cu-Tz-SarAr. Among these two, the later
possesses excellent pharmacokinetic properties with rapid
renal clearance. In combination with a TCO-modified conjugate
of the colorectal cancer-targeting huA33 mAb, 64Cu-Tz-SarAr was
shown to eﬃciently delineate malignant tissues in murine xeno-
grafts with a high tumour to background contrast in pretargeted
PET imaging and biodistribution experiments. Importantly, the
dosimetry calculations performed in this study suggested that the
total eﬀective radiation dose is significantly lower compared to
doses deposited by imaging using directly radiolabelled mAbs.46
The same group reported recently on the development of a
novel 18F-based pretargeted PET imaging system. Therein the
authors described the production of immunoconjugates
composed of TCO moieties and mAbs (5B1) specific for the
carbohydrate antigen 19.9 (CA19.9), a biomarker for pancreatic
ductal adenocarcinoma. As complementary bioorthogonal species
to 5B1-TCO, aluminium-[18F]fluoride-NOTA-labelled Tz ligands
were synthesised and injected into CA19.9-expressing murine
xenografts 72 h after the administration of 5B1-TCO. Tumoural
uptake of the radiolabelled eﬀector was immediately evident
already 1 h postinjection and tumour-to-background activity
concentration ratios improved over time.47
Recently, diﬀerent nanoparticles have been proposed to replace
tumour antigen specific mAbs as target specific component to
target a broad range of diﬀerent tumour entities.48 Such nano-
particulate materials with in vivo hydrodynamic diameters
above the glomerular filtration threshold and prolonged blood
circulation passively accumulate in tumours through the EPR
eﬀect.49 This process depends on their leaky vasculature and
a poorly functional lymph system and results in increased
permeability to nanomaterials.
A new IEDDA-based pretargeting approach using nano-
particles was very recently introduced by Lin and co-workers.
Instead of using TCO-modified immunoconjugates, the TCO
reactive moiety was encapsulated into supramolecular nano-
particles with a uniform size of B100 nm. Small and fast
clearing eﬀector possessing the complementary bioorthogonal
motif Tz-DOTA was synthesised and radiolabelled with 64Cu.
Their in vivo pretargeting experiment started with intrave-
nous injection of the TCO-functionalised nanoparticles into
xenografted mice. After a pretargeting interval of 24 h, radio-
labelled Tz-DOTA was administered and various PET images
were taken at diﬀerent time points (Fig. 10). Strong PET signals
were observed at the tumour site with highest tumour to liver
signal ratio after 24 h postinjection. Notwithstanding this
impressive performance, also radioactivity levels in the liver
were observed, most likely due to trapping of the nanoparticles
by the mononuclear phagocyte system (MPS) or transchelation
of 64Cu from DOTA in vivo.48 Although the EPR eﬀect is a
common phenomenon in rodent models using subcutaneous
Fig. 10 (a) Timeline of the injection protocol employed for the pretargeted
study. (b) MicroPET images of the pretargeted study at various time points.
(c) Ratio of PET tumour signal to liver signal of xenografted mice from the
preliminary pretargeted study (n = 4). Adapted with permission from ref. 48
copyright American Chemical Society.
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and orthotopic xenografts, its occurrence in human primary
and metastatic lesions may be less widespread and less pro-
nounced. As nanomaterials bypassing the renal filtration process
will, however, inevitably end up in the organs of the MPS (spleen
and liver),49 also these organs will be exposed to radiation upon
injection of the radiolabelled eﬀector molecules as also observed
by Lin and co-workers.48 This crucial aspect has to be kept in
mind especially for therapeutic applications of this pretargeting
system.
In addition to the detection of tumour-bound fluorescent or
radioactive eﬀector molecules, the pretargeting concept has
recently been extended to ultrasound imaging. In order to
demonstrate the capture of gas-filled micron-sized bubbles by
means of IEDDA, the group of John F. Valliant developed
Tz-functionalised microbubbles and modified vascular endo-
thelial growth factor receptor 2 (VEGFR2) specific mAbs with
TCO. In their in vivo study, VEGFR2-positive murine xenografts
were pretargeted using the TCO-conjugated mAbs and 24 h
later the Tz-functionalised microbubbles were injected intrave-
nously. Ultrasound images acquired 4 min thereafter showed
high retention of the microbubbles in vascularised regions of
the tumours with significant contrast enhancement compared
to mice without TCO–mAb pretreatment.50
5. Conclusion and outlook
Preclinical and clinical studies have clearly indicated that
tumour pretargeting can overcome important limitations of
conventional directly radiolabelled mAbs. Since its introduction
in the mid-1980s, various pretargeting strategies have been
developed and progressed steadily over the years.
The system based on bs mAbs and the avidin/streptavidin–
biotin components represents without any doubt the most
advanced tumour pretargeting approach for diagnosis as well
as for therapy in the clinical settings, to date. However, this
system suffers from several drawbacks including induction of
immunogenicity and, therefore, future research should be
directed to tackle this important issue. Emerging pretargeting
systems based on hybridisation of synthetic complementary
oligonucleotides or bioorthogonal chemistry in vivo have the
potential to circumvent many of the limitations associated with
the avidin/streptavidin–biotin system. These approaches are
still in the preclinical stage, but possess immense potential.
Regarding bioorthogonal chemistry, IDEEA appears to be the
most suitable of all reactions tested so far for pretargeting due
to easy synthetic access of the required substrates, in vivo
stability of the TCO and Tz moieties and relatively fast reaction
kinetics. However, the kinetics of IDEEA still need further
improvement to become truly applicable in the clinic. This
could be achieved, for example, by introducing suitable modi-
fications either on the TCO or on the Tz moieties. Since the
pretargeting approach is a rapidly growing field, new bioortho-
gonal reactions with even faster reaction kinetics and better
in vivo compatibility will certainly be discovered in the near
future.
As the special strength of tumour pretargeting is the sub-
stantial reduction of healthy tissue exposure, it is in particular
useful for therapeutic purposes. At this point, it is worth
emphasizing that conventional treatments such as chemo-
therapy, external beam radiation and surgery still play a key
role in cancer management. As tumour pretargeting is suitable
for detecting tumours and metastases of minimal or micro-
scopic size, it can be indeed applied to treat and eradicate
residual disease and metastatic lesions. Furthermore, the pre-
targeting strategy can have a significant impact on the treatment
of malignant tissues that are diﬃcult to remove by surgery
or surrounded by sensitive tissues susceptible to damage. For
therapeutic purposes, it is however of utmost importance to
deposit as much radiation as possible precisely in the tumour
without harming bone marrow, liver, spleen and kidney. Since
the blood clearance of the radionuclide-carrying small eﬀector
molecules occurs suﬃciently rapid, bone marrow exposure and
haematological toxicity is less a decisive factor. And as long as
the renal clearable radiolabelled eﬀectors are not retained in the
kidneys or bladder but eliminated in the urine, renal doses are
acceptable.10 However, not only the pharmacokinetic behaviour
of the radiolabelled eﬀector molecules determines the eﬀective-
ness of the pretargeting strategy, but also the in vivo stability of
the radiometal–chelate complexes. For that reason, considerable
efforts should be devoted to the development of very stable
radiometal complexes for conjugation to the fast clearing effec-
tor molecules that permit simultaneously imaging, dosimetry
and treatment of tumours.
Although initial clinical studies of pretargeted RIT have been
very encouraging, its full potentials are yet to be proven using large
clinical trials in the near future, if thereby administered doses are
suﬃcient to result in a significant improvement in responses. It
should be noted that pretargeting is a relatively complex procedure
that might need exhaustive optimisation for its successful transla-
tion into clinic. The combination of pretargeted RIT with other
treatment modalities such as conventional external beam radia-
tion or chemotherapy might be reasonable. In particular, the
treatment with radiosensitising or anti-angiogenic agents can
produce synergistic eﬀects when combined with pretargeted RIT.
With regard to oncotropic vector molecules, tumour antigen
specific mAbs represent an essential platform to precisely detect
and treat tumour malignancies due to their excellent target
specificity and aﬃnity.4 To preserve this unmatched perfor-
mance, their chemical modification necessary to create the
desired mAb conjugates must not aﬀect their immunoreactivity
and aﬃnity and should result in a homogenous population
of bioconjugates. However, conventional bioconjugation such
as random coupling to lysine or cysteine residues result in
complex mixtures of mAb conjugates with possibly divergent
pharmacokinetic behaviour, stability and immunoreactivity.
In contrast, controlled, site-specific bioconjugation strategies
including chemoenzymatic methods have the potential to yield
more homogeneous products and should be pursued conse-
quently for the production of next-generation mAb conjugates.
Another serious problem of the pretargeting approach, which
will need to be dealt with in the future, is the partial cellular
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internalisation of mAbs upon specific interaction with their
respective cell surface-located receptors. Antigen–mAb pairs
known to internalise readily to a large extent are hence sub-
optimal for pretargeting as the prelocalised mAb conjugates
must remain accessible to form the radioimmunoconjugates
with the radiolabelled effector molecules.11 In consequence,
a whatsoever modification of mAb conjugates preventing
their receptor-mediated internalisation would represent a
key milestone for tumour pretargeting.
Finally, pretargeting approaches based on mAbs are limited
to detect and treat populations of cancerous cells with unique
or highly abundant surface markers that are located on the cell
surface of at least some, ideally on the majority of tumour cells
and, most importantly, that are readily accessible by circulating
agents. A substantial advantage of delivering therapeutic radio-
nuclides, especially b-particles, is their long range in tissues
(up to 12 mm). This allows for the irradiation of tumour cells
including cancer stem cells located adjacent to cells to which
the radioimmunoconjugates are attached. Consequently, also
tumour cell subtypes lacking the addressed antigens are
exposed to radiation.6 Targeting of a single type of cell surface
receptors may, however, allow some cancer cells to survive by
downregulation or mutation of the addressed antigen and may
permit renewed tumour growth and clinical relapse. Pretargeted
radioimmunotherapy should thus be applied in combination with
other anticancer therapies and should ideally hit a set of diﬀerent
tumour-associated antigens.
In summary, there is much space to optimise the main
parameters and improve the eﬀectiveness of the pretargeting
approach. Only if significant benefits for patients can be clearly
illustrated in clinical studies, will this technology be translated
into practise and impact in the clinics.
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